ESTRADIOL

First approved in 1940

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H24O2
Molecular Weight	272.3826
Optical Activity	( + )
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@]12CC[C@]3([H])c4ccc(cc4CC[C@@]3([H])[C@]2([H])CC[C@]1([H])O)O

InChI

InChIKey=VOXZDWNPVJITMN-ZBRFXRBCSA-N

InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C18H24O2
Molecular Weight	272.3826
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://pubchem.ncbi.nlm.nih.gov/compound/222757https://www.ncbi.nlm.nih.gov/pubmed/11250930http://www.drugbank.ca/drugs/DB00783
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020375s027lbl.pdf

Estradiol an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. In humans, it is produced primarily by the cyclic ovaries and the placenta. It is also produced by the adipose tissue of men and postmenopausal women. The 17-alpha-isomer of estradiol binds weakly to estrogen receptors (receptors, estrogen) and exhibits little estrogenic activity in estrogen-responsive tissues. Estradiol enters target cells freely (e.g., female organs, breasts, hypothalamus, pituitary) and interacts with a target cell receptor. When the estrogen receptor has bound its ligand it can enter the nucleus of the target cell, and regulate gene transcription which leads to formation of messenger RNA. The mRNA interacts with ribosomes to produce specific proteins that express the effect of estradiol upon the target cell. Estradiol is used for the treatment of urogenital symptoms associated with post-menopausal atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria). Estradiol is marketed under the brand name Climara (among others), indicated for: the treatment of moderate to severe vasomotor symptoms due to menopause, treatment of symptoms of vulvar and vaginal atrophy due to menopause, treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure and prevention of postmenopausal osteoporosis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Steryl-sulfatase 30 Target ID: P08842 Gene ID: 412 Gene Symbol: STS Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/11250930	Substrate 609
Estrogen receptor alpha 123 Target ID: CHEMBL206 Sources: http://www.drugbank.ca/drugs/DB00783	Agonist 2456	Vaginal atrophy Postmenopausal osteoporosis Primary ovarian failure	0.00839999999999999948 nM [EC50]
Estrogen receptor beta 106 Target ID: CHEMBL242 Sources: http://www.drugbank.ca/drugs/DB00783	Agonist 2456	Primary ovarian failure Postmenopausal osteoporosis Vaginal atrophy	1.39999999999999991 nM [EC50]
Androgen Receptor 163 Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16309907	Antagonist 2577		19.1000000000000014 nM [IC50]
Estrogen receptor alpha 123 Target ID: CHEMBL206 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/222757	Agonist 2456		0.130000000000000004 nM [Ki]
Estrogen receptor beta 106 Target ID: CHEMBL242 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/222757	Agonist 2456		0.0899999999999999967 nM [Kd]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Vaginal atrophy 27 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020375s027lbl.pdf	Primary	Estrogen receptor alpha Estrogen receptor beta	Approved 7997	CLIMARA Approved Use Climara is an estrogen indicated for: •Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause •Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause •Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure •Prevention of Postmenopausal Osteoporosis Launch Date 157680000000
Postmenopausal osteoporosis 59 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020375s027lbl.pdf	Preventing	Estrogen receptor alpha Estrogen receptor beta	Approved 7997	CLIMARA Approved Use Climara is an estrogen indicated for: •Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause •Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause •Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure •Prevention of Postmenopausal Osteoporosis Launch Date 157680000000
Primary ovarian failure 27 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020375s027lbl.pdf	Primary	Estrogen receptor alpha Estrogen receptor beta	Approved 7997	CLIMARA Approved Use Climara is an estrogen indicated for: •Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause •Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause •Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure •Prevention of Postmenopausal Osteoporosis Launch Date 157680000000

C_max

Value	Dose	Co-administered	Analyte	Population
14.7 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022038s005s006lbl.pdf	0.25 mg 1 times / day steady-state, topical dose: 0.25 mg route of administration: Topical experiment type: STEADY-STATE co-administered:		ESTRADIOL plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN
92 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020655s020lbl.pdf	0.05 mg 1 times / day multiple, topical dose: 0.05 mg route of administration: Topical experiment type: MULTIPLE co-administered:		ESTRADIOL plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
236 pg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022038s005s006lbl.pdf	0.25 mg 1 times / day steady-state, topical dose: 0.25 mg route of administration: Topical experiment type: STEADY-STATE co-administered:		ESTRADIOL plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
10 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022038s005s006lbl.pdf	0.25 mg 1 times / day steady-state, topical dose: 0.25 mg route of administration: Topical experiment type: STEADY-STATE co-administered:		ESTRADIOL plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN
1.75 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020655s020lbl.pdf	0.05 mg 1 times / day multiple, topical dose: 0.05 mg route of administration: Topical experiment type: MULTIPLE co-administered:		ESTRADIOL plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1470	substrate 865	substrate 1038

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP1B1 82 CYP1A1 302 CYP1A2 892 CYP3A5 346 CYP3A7 104 CYP2C18 143 CYP2E1 567 CYP2A6 452 CYP2B6 575 CYP2C8 586 CYP2C19 830 UGT1A1 358 UGT1A3 358 UGT1A4 295 UGT1A5 51 UGT1A6 258 UGT1A7 197 UGT1A8 242 UGT1A9 327 UGT1A10 247 UGT2A2 46 UGT2A3 46 UGT2B4 213 UGT2B7 329 UGT2B10 112 UGT2B17 184 UGT2B28 57	CYP2B6 486

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2B6 845	inducer 1333 Sources: https://www.sciencedirect.com/science/article/pii/S0006295212002328 Page: -	yes
P-gp 1255	supressor 128 Sources: https://pubs.acs.org/doi/abs/10.1021/mp900077q Page: -	yes

Drug as victim

Target	Modality	Activity
CYP2A6 452	substrate 2752 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	minor
CYP2B6 575	substrate 2752 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	minor
CYP2C19 830	substrate 2752 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	minor
CYP2C8 586	substrate 2752 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	minor
CYP2C9 865	substrate 2752 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	minor
CYP2D6 1038	substrate 2752 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	minor
CYP2C18 143	substrate 2752 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	no
CYP2E1 567	substrate 2752 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	no
UGT1A5 51	substrate 2752 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	no
UGT1A6 258	substrate 2752 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	no
UGT1A7 197	substrate 2752 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	no
UGT1A9 327	substrate 2752 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	no
UGT2B10 112	substrate 2752 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	no
UGT2B28 57	substrate 2752 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	no
UGT2B4 213	substrate 2752 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	no
UGT1A1 358	substrate 2752 Sources: https://dmd.aspetjournals.org/content/30/11/1266.short Page: -	yes [Km 7 uM]
CYP1A1 302	substrate 2752 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	yes
CYP1A2 892	substrate 2752 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	yes
CYP1B1 82	substrate 2752 Sources: https://www.pnas.org/content/93/18/9776.short Page: -	yes
CYP3A4 1470	substrate 2752 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	yes
CYP3A5 346	substrate 2752 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	yes
CYP3A7 104	substrate 2752 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	yes
UGT1A10 247	substrate 2752 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	yes
UGT1A3 358	substrate 2752 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	yes
UGT1A4 295	substrate 2752 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	yes
UGT1A8 242	substrate 2752 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	yes
UGT2A2 46	substrate 2752 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	yes
UGT2A3 46	substrate 2752 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	yes
UGT2B17 184	substrate 2752 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	yes
UGT2B7 329	substrate 2752 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	yes

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P0035A6
A2B Chem	AB46014
AChemBlock	P51002
AK Scientific	1084AH
AK Scientific	2119AH
AK Scientific	H061
AK Scientific	J10189
APExBIO	A8425
AbovChem LLC	HY-B0141
Accela ChemBio Inc	SY017569
Acros Organics	43632
Alfa Chemistry	L03801
Angene	AGN-PC-0RASHD
Angene	AGN-PC-0S7GCK
AstaTech	30740
BOC Sciences	50-28-2
Bide Pharmatech	BD289386
BioSynth	Q-201503
Bosche Scientific	E0342
Cayman Chemical	10006315
Chem Scene	CS-1938
ChemShuttle	151491
Chemik	CHB85579
Combi-Blocks	QA-4119
Compound Cloud	154274
Compound Cloud	5757
Enamine	EN300-119518
Fluorochem	358087
Fluorochem	393318
Hangzhou APIChem Technology	AC-22346
Hangzhou APIChem Technology	AC-24744
Hangzhou Yuhao Chemical Technology	LT1224
HongKong Chemhere	SCA38521
IBScreen	Bio-0812
Innovapharm	BBS-00029263
KeyOrganics	AS-13729
Lab Network	LN00235694
Lab Seeker	SC-25771
MedChem Express	HY-B0141
MolPort	MolPort-001-794-632
Molnova	M14702
PI Chemicals	PI-12366
Ryan Scientific	Daidzein
Selleck Chemicals	S1709
ShangHai Biochempartner	BCP08579
Sigma Aldrich	1250008
Sigma Aldrich	1250008\|USP
Sigma Aldrich	31734
Sigma Aldrich	31734\|SIAL
Sigma Aldrich	BP729
Sigma Aldrich	E-060
Sigma Aldrich	E-060\|CERILLIAN
Sigma Aldrich	E-073\|CERILLIAN
Sigma Aldrich	E-117\|CERILLIAN
Sigma Aldrich	E1024
Sigma Aldrich	E1024\|SIGMA
Sigma Aldrich	E1132
Sigma Aldrich	E1132\|SIGMA
Sigma Aldrich	E125
Sigma Aldrich	E125\|SIGMA
Sigma Aldrich	E1620000
Sigma Aldrich	E1620000\|SIAL
Sigma Aldrich	E2257
Sigma Aldrich	E2257\|SIGMA
Sigma Aldrich	E2758
Sigma Aldrich	E2758\|SIGMA
Sigma Aldrich	E8875
Sigma Aldrich	E8875\|SIGMA
Sigma Aldrich	PHR1353
Sigma Aldrich	PHR1353\|SIAL
Specs	AA-504/07225009
StruChem	SC-25771
TargetMol	50-28-2
TargetMol	BBP03440
TargetMol	HMDB0000151
TargetMol	T1048
Tetrahedron	TS33409
Tocris	2824
Toronto Research Chemicals	E888000
Vitas-M Laboratory	BBL010481
W&J PharmaChem	50A228703
ZINC	ZINC000013520815	http://zinc15.docking.org/substances/ZINC000013520815
eMolecules	195112133
eMolecules	29549878
eMolecules	43213766
eMolecules	888945
mcule	MCULE-1095311163
mcule	MCULE-2217552374

PubMed

Title	Date	PubMed
Effect of estradiol benzoate on the proliferation of osteogenic cells in fetal rat fibulae cultured in vitro.	1978 Mar	674716
An increase of pituitary 3', 5' cyclic adenosine monophosphate produced by estradiol benzoate in vitro: possible implication of this increase in the secretion of luteinizing hormone.	1978 May	208943
Sulfation of estrone and 17 beta-estradiol in human liver. Catalysis by thermostable phenol sulfotransferase and by dehydroepiandrosterone sulfotransferase.	1992 May-Jun	1355717
[The effect of adrenaline and 17beta-estradiol sulfate on transmembrane potentials of guinea pig cardiomyocytes].	1996 Dec	9280454
Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.	1997 Mar	9048584
Indole-3-carbinol is a negative regulator of estrogen receptor-alpha signaling in human tumor cells.	2000 Dec	11110848
Estrogen activation of the nuclear orphan receptor CAR (constitutive active receptor) in induction of the mouse Cyp2b10 gene.	2000 Nov	11075820
Estradiol enhances the resistance of LDL to oxidation by stabilizing apoB-100 conformation.	2000 Nov 14	11076531
Relative binding affinity does not predict biological response to xenoestrogens in rat endometrial adenocarcinoma cells.	2000 Oct	11086226
Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta.	2000 Oct	11014220
Constitutive expression of the steroid sulfatase gene supports the growth of MCF-7 human breast cancer cells in vitro and in vivo.	2001 Apr	11250930
Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer.	2001 Apr 6	11063747
Vitellogenin-induced pathology in male summer flounder (Paralichthys dentatus).	2001 Feb	11090901
Use of salivary biomarkers in biobehavioral research: cotton-based sample collection methods can interfere with salivary immunoassay results.	2001 Feb	11087962
Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells.	2001 Feb 2	11044445
Effects of follicle-stimulating hormone with and without luteinizing hormone on serum hormone concentrations, follicle growth, and intrafollicular estradiol and aromatase activity in gonadotropin-releasing hormone-immunized heifers.	2001 Jan	11133695
Female steroid hormones modulate receptors for nerve growth factor in rat dorsal root ganglia.	2001 Jan	11133691
Regulation and role of vascular endothelial growth factor in the corpus luteum during mid-pregnancy in rats.	2001 Jan	11133689
Increased expression of a novel heat shock protein transcript in the mouse uterus during decidualization and in response to progesterone.	2001 Jan	11133685
Regulation of progesterone receptors and decidualization in uterine stroma of the estrogen receptor-alpha knockout mouse.	2001 Jan	11133684
Pregnancy stimulates secretion of adrenocorticotropin and nitric oxide from peripheral bovine lymphocytes.	2001 Jan	11133680
Estradiol-induced attenuation of pulmonary hypertension is not associated with altered eNOS expression.	2001 Jan	11133498
Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.	2001 Jan	11125427
Metabolism of estradiol, ethynylestradiol, and moxestrol in rat uterus, vagina, and aorta: influence of sex steroid treatment.	2001 Jan	11124233
Rapid and reversible inhibition of brain aromatase activity.	2001 Jan	11123516
Oestrogen-induced changes in the synaptology of the monkey (Cercopithecus aethiops) arcuate nucleus during gonadotropin feedback.	2001 Jan	11123512
Stimulatory effect of clofibrate and gemfibrozil administration on the formation of fatty acid esters of estradiol by rat liver microsomes.	2001 Jan	11123380
Influence of gender and sex hormones on nicotine acute pharmacological effects in mice.	2001 Jan	11123373
Heat-shock factor-1, steroid hormones, and regulation of heat-shock protein expression in the heart.	2001 Jan	11123263
Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle.	2001 Jan	11121374
Dose-response relationships and pharmacokinetics of vitellogenin in rainbow trout after intravascular administration of 17alpha-ethynylestradiol.	2001 Jan	11090892
Evaluation of an EIA method for measuring serum levels of the estrogen metabolite 2-hydroxyestrone in adults.	2001 Jan	11090660
Estradiol levels in psychotic disorders.	2001 Jan	11070332
Neuroprotection by estradiol.	2001 Jan	11040417
Effects of heterocyclic amines with mammary gland carcinogenic potential on estrogenic response of uterus in ovariectomized rats.	2001 Jan 10	11121860
Affinity labeling of rat glutathione S-transferase isozyme 1-1 by 17beta -iodoacetoxy-estradiol-3-sulfate.	2001 Jan 19	11031273
Reduction of gamma-aminobutyric acid-ergic neurotransmission as a putative mechanism of radiation induced activation of the gonadotropin releasing-hormone-pulse generator leading to precocious puberty in female rats.	2001 Jan 5	11114481
Hormone binding by protein disulfide isomerase, a high capacity hormone reservoir of the endoplasmic reticulum.	2001 Jan 5	11035025
Acquisition of Lubrol insolubility, a common step for growth hormone and prolactin in the secretory pathway of neuroendocrine cells.	2001 Jan 5	11024038
In vivo regulation of syndecan-3 expression in the rat uterus by 17 beta-estradiol.	2001 Jan 5	11024013
Glutathione stimulates sulfated estrogen transport by multidrug resistance protein 1.	2001 Mar 2	11102445
Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation.	2001 Mar 23	11121427
Enhanced multispecificity of arabidopsis vacuolar multidrug resistance-associated protein-type ATP-binding cassette transporter, AtMRP2.	2001 Mar 23	11115509
The unusual binding properties of the third distinct teleost estrogen receptor subtype ERbetaa are accompanied by highly conserved amino acid changes in the ligand binding domain.	2004 Jun	15001543
Sulfonation of 17beta-estradiol and inhibition of sulfotransferase activity by polychlorobiphenylols and celecoxib in channel catfish, Ictalurus punctatus.	2007 Mar 10	17239972
Complex actions of estradiol-3-sulfate in late gestation fetal brain.	2011 Jul	21273638
[Study of gonadal hormone drugs in blocking filovirus entry of cells in vitro].	2015 Dec	27169275
Evaluation of Effects of Topical Estradiol Benzoate Application on Cutaneous Wound Healing in Ovariectomized Female Mice.	2016	27658263
Effects of Exposure to Estradiol Benzoate or Flutamide at the Weaning Age on Expression of Connexins in the Caudal Epididymis of Adult Rat.	2016 Dec	28144639
Changes in Expression of Connexin Isoforms in the Caudal Epididymis of Adult Sprague-Dawley Rats exposed to Estradiol Benzoate or Flutamide at the Neonatal Age.	2016 Sep	27796005

Patents

Sample Use Guides

In Vitro Use Guide

The influence of estradiol benzoate on the proliferation of bone cells was investigated in vitro. The fibulae from 19-day fetal rats were pulse-labeled with 3H-thymidine after various periods of culture on estrogen-supplemented (5 microgram/ml) or control media. The analysis revealed that the cell division was restricted to osteogenic cells of undifferentiated appearance. No label was found in osteoblasts or in osteoclasts. At the time of explantation, about 30% of osteogenic cells were labeled. However, this percentage varied considerably after different intervals of culture. In the control bones, it decreased during first 12 hours to 15% and then rose slowly to attain a preculture value after 48 hours. In the presence of estradiol, the initial decline of labeled cells was less pronounced. The percentage recovered to a preculture level already after 24 hours and continued to increase thereafter. The numbers of labeled osteogenic cells, in estrogen-treated bones, were significantly higher than in controls already after 12 hours of culture. It is concluded that the fetal rat bones undergo in vitro a period of adaptation to a new environment as indicated by a transient decrease of dividing cells. Estradiol benzoate appears to shorten this period by stimulating the proliferation of undifferentiated cells.

Substance Class	Chemical Created by `admin` on `Fri Jun 25 21:35:34 UTC 2021` Edited by `admin` on `Fri Jun 25 21:35:34 UTC 2021`
Record UNII	4TI98Z838E
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ESTRADIOL

Official Name

English

VAGIFEM

Brand Name

English

ESTRADIOL IMPURITY A [IP]

Common Name

English

WC3011

Code

English

ESTRADIOL [VANDF]

Common Name

English

ETHINYLESTRADIOL IMPURITY D [EP]

Common Name

English

ESTRADIOL [WHO-DD]

Common Name

English

INNOFEM

Brand Name

English

ESTRA-1,3,5(10)-TRIENE-3,17-DIOL (17.BETA.)-

Common Name

English

ESTRADIOL BENZOATE SPECIFIED IMPURITY A [EP]

Common Name

English

17-.BETA.-OESTRADIOL

Common Name

English

DIVIGEL

Brand Name

English

ESTRADIOL [ORANGE BOOK]

Common Name

English

17BETA-ESTRADIOL

Common Name

English

ESTRADIOL COMPONENT OF COMBIPATCH

Common Name

English

FEMPATCH

Brand Name

English

ESTRADIOL COMPONENT OF CLIMARA PRO

Common Name

English

ESTRADIOL [GREEN BOOK]

Common Name

English

OESTRADIOL

Common Name

English

IMVEXXY

Brand Name

English

ESTRADIOL [JAN]

Common Name

English

ELESTRIM

Brand Name

English

CLIMARA

Brand Name

English

NSC-20293

Code

English

ALORA

Brand Name

English

ORIAHNN COMPONENT ESTRADIOL

Brand Name

English

13.BETA.-METHYL-1,3,5(10)-GONATRIENE-3,17.BETA.-OL

Systematic Name

English

ESTRADIOL COMPONENT OF BIJUVA

Common Name

English

E2

Common Name

English

ESTRADIOL [INN]

Common Name

English

ESTRADIOL BENZOATE IMPURITY A [EP]

Common Name

English

ESCLIM

Brand Name

English

ESTRING

Brand Name

English

EVAMIST

Brand Name

English

ESTRACE

Brand Name

English

PREFEST COMPONENT ESTRADIOL

Common Name

English

COMBIPATCH COMPONENT ESTRADIOL

Common Name

English

ESTRADIOL COMPONENT OF ANGELIQ

Common Name

English

BIJUVA COMPONENT ESTRADIOL

Common Name

English

ESTROGEL

Brand Name

English

NSC-9895

Code

English

WC-3011

Code

English

ESTRADIOL [HSDB]

Common Name

English

ESTRADIOL VALERATE METABOLITE E2

Common Name

English

MENOSTAR

Brand Name

English

ESTRADIOL COMPONENT OF ACTIVELLA

Common Name

English

ESTRADIOL ANHYDROUS

Common Name

English

17.BETA.-ESTRADIOL

Common Name

English

ESTRADIOL [USP]

Common Name

English

ESTRADERM

Brand Name

English

3,17.BETA.-DIHYDROXYESTRA-1,3,5(10)-TRIENE

Systematic Name

English

GYNODIOL

Brand Name

English

ESTRADIOL 17-BETA

Common Name

English

ESTRADIOL 17-BETA [VANDF]

Common Name

English

ESTRADIOL [MI]

Common Name

English

ESTRADIOL [INCI]

Common Name

English

CLIMARA PRO COMPONENT ESTRADIOL

Common Name

English

ESTRADIOL VALERATE IMPURITY A [EP]

Common Name

English

(+)-3,17.BETA.-ESTRADIOL

Systematic Name

English

ESTRA-1,3,5(10)-TRIENE-3,17.BETA.-DIOL

Systematic Name

English

VIVELLE

Brand Name

English

ESTRADIOL COMPONENT OF ORIAHNN

Brand Name

English

17-BETA-OESTRADIOL

Common Name

English

ANGELIQ COMPONENT ESTRADIOL

Common Name

English

ESTRADIOL [USP-RS]

Common Name

English

ACTIVELLA COMPONENT ESTRADIOL

Common Name

English

ESTRADIOL COMPONENT OF PREFEST

Common Name

English

Classification Tree Code System Code

LOINC

35384-7

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

34290-7

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

34286-5

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

12595-5

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

2239-2

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

WHO-ATC

G03CA03

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

WHO-VATC

QG03CA03

Created by admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021

CFR

21 CFR 522.840

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

83097-6

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

2240-0

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

14715-7

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

15062-3

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

12214-3

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

34288-1

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

FDA ORPHAN DRUG

231706

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

WHO-VATC

QG03CA53

Created by admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021

LOINC

25401-1

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

CFR

21 CFR 310.527

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

WHO-VATC

QG03AB08

Created by admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021

NDF-RT

N0000011402

Created by admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021

WHO-ATC

G03AA14

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

13883-4

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

2246-7

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

WHO-VATC

QG03AA14

Created by admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021

CFR

21 CFR 556.240

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

72873-3

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

34287-3

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

55857-7

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

35207-0

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

21263-9

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LIVERTOX

372

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

2243-4

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

2245-9

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

2238-4

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

31176-1

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

WHO-ATC

G03CA53

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

WHO-ATC

G03AB08

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

14960-9

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

2241-8

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

EMA ASSESSMENT REPORTS

IOA (WITHDRAWN: CONTRACEPTION)

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

NDF-RT

N0000000100

Created by admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021

LOINC

12213-5

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

34291-5

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

CFR

21 CFR 522.2477

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

NDF-RT

N0000175825

Created by admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021

LOINC

44730-0

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

34289-9

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

CFR

21 CFR 862.1430

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

CFR

21 CFR 862.1260

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

NCI_THESAURUS

C2293

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

13736-4

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

55858-5

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

83096-8

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

2242-6

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

LOINC

2244-2

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

Code System Code Type Description

IUPHAR

1013

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

PRIMARY

ECHA (EC/EINECS)

200-023-8

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

PRIMARY

WIKIPEDIA

ESTRADIOL

Created by admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021

PRIMARY

LACTMED

Estradiol

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

PRIMARY

DRUG BANK

DB00783

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

PRIMARY

EVMPD

SUB96040

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

PRIMARY

MERCK INDEX

M5028

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

PRIMARY

Merck Index

MESH

D004958

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

PRIMARY

EPA CompTox

50-28-2

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

PRIMARY

INN

406

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

PRIMARY

NCI_THESAURUS

C478

Created by admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021

PRIMARY

ChEMBL

CHEMBL135

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

PRIMARY

DRUG CENTRAL

1057

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

PRIMARY

CAS

50-28-2

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

PRIMARY

EVMPD

SUB07242MIG

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

PRIMARY

FDA UNII

4TI98Z838E

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

PRIMARY

RXCUI

4083

Created by admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021

PRIMARY

RxNorm

EVMPD

SUB21195

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

PRIMARY

HSDB

3589

Created by admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021

PRIMARY

USP_CATALOG

1250008

Created by admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021

PRIMARY

USP-RS

PUBCHEM

5757

Created by admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021

PRIMARY

Related Record Type Details


					37UIZ63WWM

SODIUM ESTRADIOL

SALT/SOLVATE -> PARENT


					0RFO7VC96N

URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A1

METABOLIC ENZYME -> SUBSTRATE


					ZIF514RVZR

ALBUMIN HUMAN

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					CXY7B3Q98Z

ESTRADIOL HEMIHYDRATE

SALT/SOLVATE -> PARENT


					LR0F81F33L

ALDEHYDE OXIDASE

METABOLIC ENZYME -> INHIBITOR

Qualification:

IC50

Amount:


					4TI98Z838E

ESTRADIOL

BASIS OF STRENGTH->SUBSTANCE

Interaction Type:

ASSAY (HPLC)

Qualification:

USP

Amount:


					AIN96D6SGL

OATP1B1

TRANSPORTER -> INHIBITOR


					IHQ709299P

URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A3

METABOLIC ENZYME -> SUBSTRATE


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> SUBSTRATE


					CXY7B3Q98Z

ESTRADIOL HEMIHYDRATE

SUBSTANCE->BASIS OF STRENGTH


					YJ0ZSQ5NF5

SEX HORMONE-BINDING GLOBULIN

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					SIDP85PFD6

ESTROGEN RECEPTOR

TARGET -> AGONIST

Related Record Type Details


					ZE4IGI4UMH

ESTRA-1,3,5(10)-TRIENE-3,17-DIOL (17.BETA.)-, 3-BENZOATE 17-BUTANOATE

PRODRUG -> METABOLITE ACTIVE


					QTL48N278K

ESTRONE SULFATE

METABOLITE -> PARENT

Comments:

E2 is then extensively metabolized to estrone (E1) (15%), estrone sulfate (E1S) (65%), and other compounds.

Amount:


					4NKQ3751P6

ESTRADIOL 3-SULFATE

METABOLITE -> PARENT


					OKG364O896

ESTRADIOL VALERATE

PRODRUG -> METABOLITE ACTIVE


					AYU2L67YUU

2-HYDROXYESTRADIOL

METABOLITE -> PARENT


					2DI9HA706A

ESTRONE

METABOLITE -> PARENT

Comments:

E2 is then extensively metabolized to estrone (E1) (15%), estrone sulfate (E1S) (65%), and other compounds.

Amount:


					N4K670423X

.DELTA.6,7-ESTRADIOL

METABOLITE LESS ACTIVE -> PARENT

Interaction Type:

IN-VITRO


					UR9WW8CA3J

ESTRADIOL PARAQUINOL

PRODRUG -> METABOLITE ACTIVE


					3XMK78S47O

TESTOSTERONE

PARENT -> METABOLITE ACTIVE


					35LT29625A

ESTRAMUSTINE

PARENT -> METABOLITE

Comments:

Metabolite produced by hydrolysis. Estramustine,s primary mechanism of antineoplastic action is inhibition of mitosis.

Qualification:

PLASMA


					3U2V78OM3M

3,4-ESTRONE QUINONE

METABOLITE -> PARENT

Interaction Type:

IN-VITRO

Qualification:

Scientific Literature


					UQS3A06ILY

2-HYDROXYESTRONE

METABOLITE -> PARENT

Interaction Type:

MAJOR


					C3ZO03450E

4-HYDROXYESTRADIOL

METABOLITE -> PARENT


					JY611949JU

16.ALPHA.-HYDROXYESTRONE

METABOLITE -> PARENT

Interaction Type:

IN-VIVO

Qualification:

URINE


					MUZ9585Y7B

ESTRAMUSTINE PHOSPHATE

PRODRUG -> METABOLITE ACTIVE

Related Record Type Details


					423D2T571U

ETHINYL ESTRADIOL

PARENT -> IMPURITY

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					1S4CJB5ZGN

ESTRADIOL BENZOATE

PARENT -> IMPURITY

Interaction Type:

CHROMATOGRAPHIC PURITY (TLC)

Qualification:

USP

Amount:


					5GTC4LE496

6.BETA.-HYDROXYESTRADIOL

IMPURITY -> PARENT


					IL75Q4KU3Q

6.ALPHA.-HYDROXYESTRADIOL

IMPURITY -> PARENT


					7E1DV054LO

ESTRADIOL CYPIONATE

PARENT -> IMPURITY


					BZ2CJW3GSE

6-KETOESTRADIOL

IMPURITY -> PARENT

Related Record Type Details


					4TI98Z838E

ESTRADIOL

ACTIVE MOIETY

Name	Property Type	Parameters
Tmax	PHARMACOKINETIC	ESTRADIOL VALERATE Single Dose

Volume of Distribution	PHARMACOKINETIC

Biological Half-life	PHARMACOKINETIC	ESTRADIOL VALERATE Single Dose

Details

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2

Drug as perpetrator